OBJECTIVE: To evaluate MAGE tumor-associated antigen (TAA) expression in an extensive panel of normal and neoplastic tissues. SUMMARY BACKGROUND DATA: TAAs of the MAGE family represent targets of active specific immunotherapy. Limited-size studies indicate that they are expressed in normal testis and tumors of different histologies. High-throughput tissue microarray (TMA) technology and MAGE TAA-specific monoclonal antibodies now allow us to comprehensively evaluate their expression in large numbers of tissues and to address clinical correlations. METHODS: A TMA containing 3,520 samples from 197 different tissues and a non-small-cell lung cancer TMA including 301 specimens were stained using the MAGE TAA-specific monoclonal antibody 57B. For patients with squamous cell carcinoma of the lung, the dichotomous result (positive vs. negative) of MAGE TAA staining was used as a predictor variable along with other covariates in proportional hazard regression analysis of tumor-specific survival. RESULTS: MAGE TAAs are expressed with frequencies ranging between 22.7% (larynx) and 50% of cases (lung) in squamous cell carcinomas from different anatomic areas and in large cell carcinomas of the lung (37.9%). The authors provide here the first description of MAGE TAA expression in basalioma (48.1%). To investigate the clinical significance of MAGE expression in a frequently positive tumor type, a non-small-cell lung cancer, TMA was then studied. In this TMA 43.2% of tumors were 57B positive. In patients with squamous cell carcinoma, MAGE TAA positivity was significantly correlated with a shorter tumor-specific survival in the proportional hazard regression analysis model. CONCLUSIONS: These data suggest novel potential therapeutic indications in different types of cancers. In lung squamous cell carcinoma, the significant association of MAGE TAA expression with poor prognosis suggests that patients with 57B-positive tumors may benefit from early, specific immunotherapy procedures.
OBJECTIVE: To evaluate MAGE tumor-associated antigen (TAA) expression in an extensive panel of normal and neoplastic tissues. SUMMARY BACKGROUND DATA: TAAs of the MAGE family represent targets of active specific immunotherapy. Limited-size studies indicate that they are expressed in normal testis and tumors of different histologies. High-throughput tissue microarray (TMA) technology and MAGE TAA-specific monoclonal antibodies now allow us to comprehensively evaluate their expression in large numbers of tissues and to address clinical correlations. METHODS: A TMA containing 3,520 samples from 197 different tissues and a non-small-cell lung cancer TMA including 301 specimens were stained using the MAGE TAA-specific monoclonal antibody 57B. For patients with squamous cell carcinoma of the lung, the dichotomous result (positive vs. negative) of MAGE TAA staining was used as a predictor variable along with other covariates in proportional hazard regression analysis of tumor-specific survival. RESULTS: MAGE TAAs are expressed with frequencies ranging between 22.7% (larynx) and 50% of cases (lung) in squamous cell carcinomas from different anatomic areas and in large cell carcinomas of the lung (37.9%). The authors provide here the first description of MAGE TAA expression in basalioma (48.1%). To investigate the clinical significance of MAGE expression in a frequently positive tumor type, a non-small-cell lung cancer, TMA was then studied. In this TMA 43.2% of tumors were 57B positive. In patients with squamous cell carcinoma, MAGE TAA positivity was significantly correlated with a shorter tumor-specific survival in the proportional hazard regression analysis model. CONCLUSIONS: These data suggest novel potential therapeutic indications in different types of cancers. In lung squamous cell carcinoma, the significant association of MAGE TAA expression with poor prognosis suggests that patients with 57B-positive tumors may benefit from early, specific immunotherapy procedures.
Authors: H Chambost; N Van Baren; F Brasseur; D Godelaine; L Xerri; S J Landi; I Theate; J Plumas; G C Spagnoli; G Michel; P G Coulie; D Olive Journal: Blood Date: 2000-06-01 Impact factor: 22.113
Authors: B Schuler-Thurner; D Dieckmann; P Keikavoussi; A Bender; C Maczek; H Jonuleit; C Röder; I Haendle; W Leisgang; R Dunbar; V Cerundolo; P von Den Driesch; J Knop; E B Bröcker; A Enk; E Kämpgen; G Schuler Journal: J Immunol Date: 2000-09-15 Impact factor: 5.422
Authors: N Sadanaga; H Nagashima; K Mashino; K Tahara; H Yamaguchi; M Ohta; T Fujie; F Tanaka; H Inoue; K Takesako; T Akiyoshi; M Mori Journal: Clin Cancer Res Date: 2001-08 Impact factor: 12.531
Authors: J Richter; U Wagner; J Kononen; A Fijan; J Bruderer; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; K Wilber; M Anabitarte; F Hering; T Hardmeier; A Schönenberger; R Flury; P Jäger; J L Fehr; P Schraml; H Moch; M J Mihatsch; T Gasser; O P Kallioniemi; G Sauter Journal: Am J Pathol Date: 2000-09 Impact factor: 4.307
Authors: P Schraml; J Kononen; L Bubendorf; H Moch; H Bissig; A Nocito; M J Mihatsch; O P Kallioniemi; G Sauter Journal: Clin Cancer Res Date: 1999-08 Impact factor: 12.531
Authors: Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank Journal: Mol Oncol Date: 2007-03-14 Impact factor: 6.603